NUNaoki Uchihara

Naoki Uchihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naoki Uchihara has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography

    by Shohei Kimura, Yutaka Yasui, Nobuharu Tamaki, Mayu Higuchi, Takuya Shima, Mina Taguchi, Yudai Yamazaki, Risa Seike, Naoki Uchihara, Yuki Tanaka, et al.

    Background/Objectives: Magnetic resonance elastography (MRE) provides an accurate and reproducible non-invasive assessment of liver stiffness and fibrosis severity in metabolic dysfunction-associated steatotic liver disease (MASLD). Although longitudinal changes in liver stiffness have been associated with clinical outcomes, the association between short-term and longitudinal changes remains unclear. This study aimed to evaluate the association between short-term and long-term changes in MRE-derived liver stiffness in patients with MASLD undergoing serial MRE assessments. Methods: In this retrospective cohort study, 100 patients with MASLD who underwent three MRE examinations at approximately baseline, 1 year, and 3 years were analyzed. Early response was defined as a ≥19% reduction in liver stiffness at the second examination relative to baseline. The association between early response and long-term liver stiffness changes was evaluated using logistic regression analysis. Results: A total of 22 patients (22%) were classified as early responders. Early responders were significantly more likely to achieve a ≥19% reduction in liver stiffness at the third MRE compared with non-early responders (59% vs. 27%, p = 0.006). In multivariable analysis adjusting for baseline liver stiffness, early response remained independently associated with long-term improvement (odds ratio 3.41, 95% CI 1.18–9.86; p = 0.023). Higher baseline liver stiffness was also associated with subsequent improvement (OR per 1 kPa increase, 1.44, 95% CI 1.11–1.87; p = 0.006). Conclusions: Early reductions in liver stiffness measured by MRE were associated with subsequent long-term improvements in patients with MASLD, suggesting that short-term MRE changes may provide insight into subsequent longer-term stiffness changes.

  • Open Access

    Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis

    by Yuki Tanaka, Nobuharu Tamaki, Hiroyuki Nakanishi, Takuya Shima, Mina Taguchi, Yudai Yamazaki, Naoki Uchihara, Risa Seike, Shohei Kimura, Junko Yagita, et al.

    Background and Aim: Hypozincemia is common in patients with liver cirrhosis; however, its impact on prognosis and the prognostic cutoff remain unclear. This study aimed to identify a prognostic serum zinc threshold using data-driven methods and to evaluate the prognostic association of zinc supplementation with overall survival (OS). Methods: Among 721 zinc treatment-naive patients with liver cirrhosis, a prognostic serum zinc threshold associated with OS was determined. OS was subsequently compared between zinc-treated and untreated patients with baseline serum zinc below this threshold. Baseline characteristics were balanced between the zinc-treated and untreated groups (n = 119 each) using propensity score matching (PSM). Results: Analyses examining the association between serum zinc levels and prognosis demonstrated a dose-dependent relationship with OS. A serum zinc level of 70 µg/dL was identified as a prognostic cutoff strongly associated with OS. Among patients with serum zinc levels p = 0.034). The adjusted hazard ratio (95% confidence interval) for OS in the zinc-treated group compared with the untreated group was 0.64 (0.44–0.94). Conclusions: A prognostic serum zinc threshold was identified in patients with liver cirrhosis, and zinc supplementation was associated with improved survival. Routine monitoring and zinc supplementation to maintain levels above this reference value may contribute to better prognosis. However, due to the retrospective design and potential residual confounding, future prospective trials are required to validate these findings.

  • Open Access

    Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds

    by Shohei Kimura, Nobuharu Tamaki, Mayu Higuchi, Takuya Shima, Mina Taguchi, Yudai Yamazaki, Risa Seike, Naoki Uchihara, Yuki Tanaka, Ryohei Kobayashi, et al.

    Background and Aims: Given the high prevalence of chronic liver diseases, non-invasive assessment of liver fibrosis is critical for screening and management of these conditions. While the FIB-4 index is widely used, its age-dependent nature may reduce specificity in older adults. The FIB-3 index, which excludes age, has been proposed as an alternative. This study aimed to compare the diagnostic performance of FIB-3 and FIB-4 for detecting advanced fibrosis across age groups using magnetic resonance elastography (MRE) as the reference standard. Methods: We retrospectively analyzed 3424 patients aged ≥30 years with chronic liver disease who underwent MRE. Advanced fibrosis was defined as liver stiffness ≥ 3.62 kPa. The cutoff values and diagnostic performance of the FIB-4 and FIB-3 indices for advanced fibrosis were evaluated within subgroups stratified by age quartiles (Q1–Q4), and the areas under the ROC curves (AUROCs) were compared using DeLong’s test. Results: Both FIB-3 and FIB-4 indices demonstrated comparable diagnostic accuracy for advanced fibrosis (AUROC 0.82 (95% CI: 0.81–0.83) for both; p = 0.70). In age-stratified analysis, the cutoff values for the FIB-4 index increased with increasing age (Q1: 1.72, Q2: 2.90, Q3: 3.66, Q4: 4.20), reflecting its age-dependent formula. In contrast, the FIB-3 index exhibited relatively minor variation in cutoff values across quartiles (Q1: 2.32, Q2: 3.52, Q3: 3.74, Q4: 3.14). Conclusions: FIB-3 index offers similar diagnostic accuracy to FIB-4 index while demonstrating more consistent performance across age groups. These findings provide evidence that FIB-3 index may be a useful alternative, particularly in older populations where FIB-4 index interpretation may be confounded by age.


  • Open Access

    Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma

    by Shun Ishido, Kaoru Tsuchiya, Yoshihito Kano, Yutaka Yasui, Kenta Takaura, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, et al.

    This study aimed to investigate the clinical usefulness of comprehensive genomic profiling (CGP) in patients with unresectable hepatocellular carcinoma who received multiple systemic therapies in real-world practice. In this study, all nine patients had gene alterations, and seven were candidates eligible for clinical trials based on the results of CGP. The median number of alterations per patient was four, and the blood sample was used in five patients with extrahepatic metastasis. We revealed the genomic information of the patients who received multiple systemic therapies and reported the utility of blood samples in patients with extrahepatic metastasis. Furthermore, the genomic status in patients treated with multiple molecular-targeted agents, including checkpoint inhibitors, would contribute to developing newer systemic agents. The molecular mechanism of hepatocellular carcinoma (HCC) is partially demonstrated. Moreover, in the patients receiving multiple molecular-targeted therapies, the gene alternations are still unknown. Six molecular-targeted therapies of unresectable HCC (uHCC) and comprehensive genomic profiling (CGP) have been approved in clinical practice. Hence, the utility of CGP in patients with uHCC treated with multiple molecular-targeted agents is investigated. The data of the patients with uHCC who received CGP tests were collected, retrospectively, between February 2021 and May 2022. Gene alterations detected by foundation testing, excluding variants of unknown significance, were reported in all nine patients. The samples for CGP were derived from liver tumor biopsy (n = 2), surgical specimens of bone metastases (n = 2), and blood (n = 5). The median number of systemic therapies was four. Seven patients were candidates eligible for clinical trials. One patient with a high tumor mutation burden (TMB) could receive pembrolizumab after CGP. This study presented genomic alternations after receiving multiple molecular-targeted therapies. However, further investigation needs to be conducted to develop personalized therapies and invent newer agents for treating HCC.


  • Open Access

    Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma

    by Hiroaki Matsumoto, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Hayakawa, Yutaka Yasui, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Shun Ishido, et al.

    Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoint inhibitors. We investigated the relationship between changes in muscle volume and treatment outcomes in patients treated with atezolizumab plus bevacizumab. Methods: Thirty-two patients with HCC who received atezolizumab plus bevacizumab as the first-line treatment between October 2020 and February 2022 were included. Skeletal muscle mass index (SMI) was calculated from the skeletal muscle area at the L3 level of the lumbar vertebrae. We compared pretreatment SMI and SMI at 6–14 weeks after administration. Results: Of the 32 patients, 18 had a decreased SMI, while 14 did not. Progression-free survival (PFS) was significantly longer in patients without SMI decrease than in patients with SMI decrease (8.5 vs. 5.8 months, p = 0.011). There were no significant differences in treatment-related adverse events between the patients with and without SMI. Presarcopenia at baseline was not significantly associated with PFS. Conclusions: Decreased SMI was significantly associated with PFS. Monitoring muscle volume during atezolizumab plus bevacizumab therapy is useful in clinical practice.